“…For example, miR-101 decreases the abilities of invasion and migration in several tumor types containing osteosarcoma in vitro [29], gastric cancer [30], prostate cancer [31], and glioblastoma [32] in vitro and in vivo, through post-transcriptional down-regulation of EZH2 . Moreover, miR-26a [33,34], miR-138 [35,36,37], miR-124 [38,39,40], miR-98 [41,42], miR-214 [42], miR-30d [43], miR-298 [44], and miR-340 [45] also participate in the post-transcriptional regulation of EZH2 in different kinds of cancer cells. For example, miR-26a inhibits epithelial–mesenchymal transition (EMT) function and up-regulates tumor suppressor genes, DAB2IP and RUNX3, through post-transcriptional repression of EZH2 in human hepatocellular carcinoma and lung carcinoma cells in vitro [33].…”